AEMD - .305
07/27 07:00 CDT
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC
Bulletin Board: AEMD) today disclosed it has entered into an agreement that
extends studies of the Aethlon Hemopurifier(R) with the U.S. Army Medical
Research Institute of Infectious Diseases (USAMRIID) under a cooperative
research and development agreement (CRADA). The Hemopurifier(R) is the
first-in-class medical device to selectively adsorb viruses and
immunosuppressive toxins from the bloodstream. The device has been designed to
enhance the benefit of antiviral drug regimens, and it provides a therapeutic
option against infectious viruses not addressed by drug and vaccine therapies.
(Logo: newscom.com
The objectives of the USAMRIID agreement include determining the therapeutic
efficacy of the Hemopurifier(R) in non-human primate studies against
hemorrhagic fever viruses, including the highly virulent Zaire strain of Ebola
(ZEBOV). Hemorrhagic viruses are potential bioterror and pandemic threats,
whose lethality prohibits the ability to conduct human studies.
Aethlon also disclosed that studies previously conducted by USAMRIID have
documented the Hemopurifier(R) captures approximately 50% of both wild type and
mutant strains of ZEBOV from fluids during one hour in vitrostudies. ZEBOV has
the highest virus case-fatality rate, up to 90% in some epidemics, with an
average case fatality rate of approximately 83% over 27 years. There have been
more outbreaks ZEBOV that any other strain of Ebola virus.
"It is an honor and privilege to have USAMRIID researchers test the
capability of our Hemopurifier(R) against Ebola and other highly lethal
pathogens," stated Aethlon Chairman and CEO, Jim Joyce. USAMRIID, located at
Fort Detrick, Maryland, is the lead laboratory for the Medical Biological
Defense Research Program, and plays a key role in national defense and in
infectious disease research. The Institute plays a key role as the only
laboratory in the Department of Defense (DOD) equipped to study Ebola and other
highly hazardous infectious agents requiring maximum containment at bio-safety
level four (BSL-4). The information contained in this press release does not
necessarily reflect the position or the policy of the government and no
official endorsement should be inferred.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for
infectious disease and cancer. Our Hemopurifier(R) represents the
first-in-class medical device to selectively adsorb viruses and
immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to
improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment
countermeasure against bioterror and pandemic threats. Additional information
regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Contacts:
Jon Cunningham
RedChip Companies Inc.
(407) 644-4256
(407) 491-4498 -cell
www.redchip.com
Dave@redchip.com
Jim Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Senior VP Finance
858.459.7800 x300
jfrakes@aethlonmedical.com
Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions, known
and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include,without limitation,the capability of the Hemopurifier(R)
to reduce viral loads and other disease conditions, includinghemorrhagic fever
viruses,the Company's ability to raise capital when needed, the Company's
ability to complete the developmentof its planned products, the ability of the
Company to obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and provide its
services, the impact of government regulations, patent protection on the
Company's proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other risk factors.
In such instances, actual results could differ materially as a result of a
variety of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's Securities
and Exchange Commission filings.
SOURCE Aethlon Medical, Inc.
(TS:AEMD;AEMD.OB;) |
